Biotica has developed BPRxTM Technology, which is a novel combinatorial library of phyto and endo cannabinoids for treating various diseases.
The endocannabinoid system (ECS) is composed of two G protein-coupled receptors (GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid ligands of such receptors, anandamide and 2-arachidonoyl-glycerol(2-AG). The ECS is a pleiotropic signalling system involved in all aspects of mammalian physiology and pathology, and for this reason it represents a potential target for the design and development of new therapeutic drugs. Over the past decades, the endocannabinoid system has been widely studied, owing to its broad range of physiological effects. ECS system encompasses a wide range of lipid mediators, proteins and receptors, which together can be considered as the ‘endocannabinoidome’
Biotica have created an extensive library of various phyto-endo cannabinoid combinations in effective dose concentrations called BPRxTM to modulate specific signaling to treat different human diseases.